Regeneron Pharmaceuticals (REGN) Long-Term Debt Repayments (2013 - 2017)

Regeneron Pharmaceuticals' Long-Term Debt Repayments history runs 5 years deep, the most recent figure standing at $57.0 million for Q1 2017.

• In Q1 2017, Long-Term Debt Repayments rose 3177.75% year-over-year to $57.0 million; the TTM figure through Dec 2017 stood at $57.0 million (up 73.78% YoY), while the FY2017 annual figure was $57.0 million, up 73.78% from the prior year.
• Long-Term Debt Repayments for Q1 2017 stood at $57.0 million, up from $20.2 million in the prior quarter.
• The five-year high for Long-Term Debt Repayments was $159.5 million in Q4 2014, with the low at -$2.0 million in Q4 2013.
• The 5-year median for Long-Term Debt Repayments is $18.4 million (2015), against an average of $39.6 million.
• The sharpest annual moves came in 2014 and 2016: Long-Term Debt Repayments surged 7981.13% in 2014, then sank 91.43% in 2016.
• Regeneron Pharmaceuticals' Long-Term Debt Repayments stood at -$2.0 million in 2013, then soared by 7981.13% to $159.5 million in 2014, then sank by 87.15% to $20.5 million in 2015, then retreated by 1.67% to $20.2 million in 2016, then soared by 182.88% to $57.0 million in 2017.
• Business Quant data shows REGN's Long-Term Debt Repayments at $57.0 million in Q1 2017, $20.2 million in Q4 2016, and $10.9 million in Q2 2016.